MMR Unbundling Policy & Supply Impact Workbench Clinical Bio-Policy Sim

Clinical & Adherence Inputs Cohort: 3.65M/yr
Cumulative missed well-child visits per additional injection appointment
CDC National Immunization Survey kindergarten baseline
Licensed FDA single-antigen measles/mumps/rubella fill lines
BLA approval, clinical bridging trials & GMP sterile facility re-qualification
Clinic ultra-cold & refrigeration cubic volume ratio vs trivalent vial
Structural Constraints
0 Active US Monovalent Licensures: Merck ceased manufacturing Attenuvax (measles), Mumpsvax, and Meruvax II in 2009. No FDA-approved monovalent alternatives exist today.
Injection Burden Surge: An unbundled schedule expands childhood immunization visits from 2 trivalent injections (12-15 mo, 4-6 yr) to 6 distinct injections (3 separate series).
Cold-Chain Saturation: Pediatric clinics require 285% refrigerated vial space, straining VFC (Vaccines for Children) storage assets.
Projected Full Series Coverage
63.1%
-30.0% vs Trivalent
Herd Immunity Status (95% Target)
CRITICAL DEFICIT
1.16M newly vulnerable/yr
National Supply Deficit
21.9M Doses/yr
ETA: 48 mo regulatory lead
Legal Mandate Enforceability
State police power vs Fed EO
Pediatric Adherence Decay Curve: Trivalent (2-Dose) vs Unbundled (6-Dose) D3 Adherence Simulator

Estimated timeline for FDA Biologics License Application (BLA), sterile fill-finish retooling, and commercial lot release for 3 distinct monovalent vaccines:

Engineering (12m)
Clinical/BLA (18m)
GMP Audit (10m)
Commercial (8m)
Month 0 (Executive Order Signed) Total Lead Time: 48 Months
Annual US Doses Demanded (6x cohort)
21.90M doses
3.65M infants × 6 single shots
Cold-Chain Clinic Space Required
10.40M L
+185% refrigeration surge
Enjoy this tool? Build your own with Super